Dual specificity protein kinase - Revision history

Michal Harel at 08:34, 18 June 2019

Michal Harel — Tue, 18 Jun 2019 08:34:53 GMT

←Older revision		Revision as of 08:34, 18 June 2019
Line 2:		Line 2:
	== Function ==		== Function ==

-	'''Dual specificity protein kinases''' are kinases which act as both tyrosine kinase and serine/threonine kinase. '''CLK1''' phosphorylates serine/arginine-rich proteins involved in pre-mRNA processing. Clk2 and Clk3 cause the redistribution of SR proteins and can regulate the alternative splicing of precursor mRNA<ref>PMID:9637771</ref>.	+	'''Dual specificity protein kinases''' are kinases which act as both tyrosine kinase and serine/threonine kinase. '''CLK1''' phosphorylates serine/arginine-rich proteins involved in pre-mRNA processing. '''Clk2''' and '''Clk3''' cause the redistribution of SR proteins and can regulate the alternative splicing of precursor mRNA<ref>PMID:9637771</ref>.

	== Structural highlights ==		== Structural highlights ==

Michal Harel at 08:34, 18 June 2019

Michal Harel — Tue, 18 Jun 2019 08:34:24 GMT

←Older revision		Revision as of 08:34, 18 June 2019
Line 2:		Line 2:
	== Function ==		== Function ==

-	'''Dual specificity protein kinases''' are kinases which act as both tyrosine kinase and serine/threonine kinase. '''CLK1''' phosphorylates serine/arginine-rich proteins involved in pre-mRNA processing.	+	'''Dual specificity protein kinases''' are kinases which act as both tyrosine kinase and serine/threonine kinase. '''CLK1''' phosphorylates serine/arginine-rich proteins involved in pre-mRNA processing. Clk2 and Clk3 cause the redistribution of SR proteins and can regulate the alternative splicing of precursor mRNA<ref>PMID:9637771</ref>.

	== Structural highlights ==		== Structural highlights ==

Michal Harel at 08:25, 18 June 2019

Michal Harel — Tue, 18 Jun 2019 08:25:01 GMT

←Older revision		Revision as of 08:25, 18 June 2019
Line 12:		Line 12:

	</StructureSection>		</StructureSection>
-	==3D structures of dual specificity protein kinase==

-	Updated on {{REVISIONDAY2}}-{{MONTHNAME\|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}
-	{{#tree:id=OrganizedByTopic\|openlevels=0\|
-
-	*CLK1 kinase domain
-
-	**[[1z57]] – hCLK1 + himenialdizine – human
-
-	**[[5j1v]], [[5j1w]], [[2vag]], [[5x8i]], [[6raa]], [[6q8p]], [[6q8k]], [[6i5l]], [[6i5k]], [[6i5i]], [[6i5h]], [[6fyo]], [[6ft9]], [[6ft8]] – hCLK1 + inhibitor<br />
-	**[[6g33]] – hCLK1 + iodotubercidine inhibitor<br />
-
-	*CLK2 kinase domain
-
-	**[[3nr9]] – hCLK2<br />
-	**[[5unp]], [[6fyl]], [[6fyk]], [[6fyi]] – hCLK2 + inhibitor<br />
-
-	*CLK3
-
-	**[[2eu9]] – hCLK3
-
-	**[[2exe]] – hCLK3 kinase domain, phosphorylated
-
-	**[[2wu6]], [[2wu7]], [[6rct]], [[6fyr]], [[6fyp]], [[6ft7]] - hCLK3 kinase domain + inhibitor
-
-	**[[3raw]] - hCLK3 kinase domain + leucettine
-
-	*CLK4 kinase domain
-
-	**[[6fyv]] – hCLK4 + inhibitor<br />
-
-	*TTK
-
-	**[[3cek]], [[3dbq]], [[2zmc]], [[6gvj]] – hTTK kinase domain<br />
-	**[[4b94]], [[4h7x]], [[4h7y]] - hTTK TPR domain<br />
-	**[[3gfw]] - hTTK kinase domain + pyrolo-pyridin ligand
-
-	**[[3h9f]] - hTTK kinase domain + pyrimidino-diazepin ligand
-
-	**[[2x9e]], [[3vqu]], [[3w1f]], [[4bhz]], [[4bi0]], [[4bi1]], [[4bi2]], [[4c4e]], [[4c4f]], [[4c4g]], [[4c4h]], [[4c4i]], [[4c4j]], [[4js8]], [[4jt3]], [[3wzj]], [[3wzk]], [[4o6l]], [[5ehl]], [[5eho]], [[5ehy]], [[5ei2]], [[5ei6]], [[5ei8]], [[5ap0]], [[5ap1]], [[5ap2]], [[5eh0]], [[4zeg]], [[6b4w]], [[5na0]], [[5n9s]], [[5n93]], [[5n87]], [[5n84]], [[5n7v]], [[6h3k]], [[6n6o]], [[4d2s]], [[4cva]], [[4cv9]], [[4cv8]], [[3wyy]], [[3wyx]] - hTTK kinase domain + inhibitor
-
-	**[[2zmd]], [[5ap3]], [[5ap4]], [[5ap5]], [[5ap6]], [[5ap7]], [[5o91]], [[5ntt]], [[5nad]], [[5mrb]] - hTTK kinase domain (mutant) + inhibitor<br />
-
-	**[[3hmn]] - hTTK kinase domain + ATP
-
-	**[[3hmo]] - hTTK kinase domain + staurosporine
-
-	**[[3hmp]] - hTTK kinase domain + quinazoline ligand<br />
-	**[[5ljj]] - hTTK kinase domain + reversine<br />
-	}}
	== References ==		== References ==
	<references/>		<references/>
	[[Category:Topic Page]]		[[Category:Topic Page]]

Michal Harel at 08:23, 18 June 2019

Michal Harel — Tue, 18 Jun 2019 08:23:46 GMT

←Older revision		Revision as of 08:23, 18 June 2019
Line 7:		Line 7:

	The dual specificity protein kinase '''TTK''' or '''monopolar spindle kinase 1''' contains tetratricopeptide repeat domain (TPR) which serves as interaction domain between proteins. The TPR domain is a helical 34 amino acid motif which is found in several copies in a protein which fold together forming a protein-protein binding domain. Cancer therapy potential drugs bind in <scene name='46/468134/Cv/3'>TTK active site</scene>.<ref>PMID:9779990</ref><ref>PMID:21159646</ref>		The dual specificity protein kinase '''TTK''' or '''monopolar spindle kinase 1''' contains tetratricopeptide repeat domain (TPR) which serves as interaction domain between proteins. The TPR domain is a helical 34 amino acid motif which is found in several copies in a protein which fold together forming a protein-protein binding domain. Cancer therapy potential drugs bind in <scene name='46/468134/Cv/3'>TTK active site</scene>.<ref>PMID:9779990</ref><ref>PMID:21159646</ref>
		+
		+	==3D structures of dual specificity protein kinase==
		+	[[Dual specificity protein kinase 3D structures]]
		+
	</StructureSection>		</StructureSection>
	==3D structures of dual specificity protein kinase==		==3D structures of dual specificity protein kinase==
Line 17:		Line 21:
	**[[1z57]] – hCLK1 + himenialdizine – human		**[[1z57]] – hCLK1 + himenialdizine – human

-	**[[5j1v]], [[5j1w]], [[2vag]], [[5x8i]] – hCLK1 + inhibitor<br />	+	**[[5j1v]], [[5j1w]], [[2vag]], [[5x8i]], [[6raa]], [[6q8p]], [[6q8k]], [[6i5l]], [[6i5k]], [[6i5i]], [[6i5h]], [[6fyo]], [[6ft9]], [[6ft8]] – hCLK1 + inhibitor<br />
	**[[6g33]] – hCLK1 + iodotubercidine inhibitor<br />		**[[6g33]] – hCLK1 + iodotubercidine inhibitor<br />

Line 23:		Line 27:

	**[[3nr9]] – hCLK2<br />		**[[3nr9]] – hCLK2<br />
-	**[[5unp]] – hCLK2 + inhibitor<br />	+	**[[5unp]], [[6fyl]], [[6fyk]], [[6fyi]] – hCLK2 + inhibitor<br />

	*CLK3		*CLK3
Line 31:		Line 35:
	**[[2exe]] – hCLK3 kinase domain, phosphorylated		**[[2exe]] – hCLK3 kinase domain, phosphorylated

-	**[[2wu6]], [[2wu7]] – hCLK3 kinase domain + inhibitor	+	**[[2wu6]], [[2wu7]], [[6rct]], [[6fyr]], [[6fyp]], [[6ft7]] - hCLK3 kinase domain + inhibitor

	**[[3raw]] - hCLK3 kinase domain + leucettine		**[[3raw]] - hCLK3 kinase domain + leucettine
		+
		+	*CLK4 kinase domain
		+
		+	**[[6fyv]] – hCLK4 + inhibitor<br />

	*TTK		*TTK

-	**[[3cek]], [[3dbq]], [[2zmc]] – hTTK kinase domain<br />	+	**[[3cek]], [[3dbq]], [[2zmc]], [[6gvj]] – hTTK kinase domain<br />
	**[[4b94]], [[4h7x]], [[4h7y]] - hTTK TPR domain<br />		**[[4b94]], [[4h7x]], [[4h7y]] - hTTK TPR domain<br />
	**[[3gfw]] - hTTK kinase domain + pyrolo-pyridin ligand		**[[3gfw]] - hTTK kinase domain + pyrolo-pyridin ligand
Line 43:		Line 51:
	**[[3h9f]] - hTTK kinase domain + pyrimidino-diazepin ligand		**[[3h9f]] - hTTK kinase domain + pyrimidino-diazepin ligand

-	**[[2x9e]], [[3vqu]], [[3w1f]], [[4bhz]], [[4bi0]], [[4bi1]], [[4bi2]], [[4c4e]], [[4c4f]], [[4c4g]], [[4c4h]], [[4c4i]], [[4c4j]], [[4js8]], [[4jt3]], [[3wzj]], [[3wzk]], [[4o6l]], [[5ehl]], [[5eho]], [[5ehy]], [[5ei2]], [[5ei6]], [[5ei8]], [[5ap0]], [[5ap1]], [[5ap2]], [[5eh0]], [[4zeg]], [[6b4w]], [[5na0]], [[5n9s]], [[5n93]], [[5n87]], [[5n84]], [[5n7v]] - hTTK kinase domain + inhibitor	+	**[[2x9e]], [[3vqu]], [[3w1f]], [[4bhz]], [[4bi0]], [[4bi1]], [[4bi2]], [[4c4e]], [[4c4f]], [[4c4g]], [[4c4h]], [[4c4i]], [[4c4j]], [[4js8]], [[4jt3]], [[3wzj]], [[3wzk]], [[4o6l]], [[5ehl]], [[5eho]], [[5ehy]], [[5ei2]], [[5ei6]], [[5ei8]], [[5ap0]], [[5ap1]], [[5ap2]], [[5eh0]], [[4zeg]], [[6b4w]], [[5na0]], [[5n9s]], [[5n93]], [[5n87]], [[5n84]], [[5n7v]], [[6h3k]], [[6n6o]], [[4d2s]], [[4cva]], [[4cv9]], [[4cv8]], [[3wyy]], [[3wyx]] - hTTK kinase domain + inhibitor

	**[[2zmd]], [[5ap3]], [[5ap4]], [[5ap5]], [[5ap6]], [[5ap7]], [[5o91]], [[5ntt]], [[5nad]], [[5mrb]] - hTTK kinase domain (mutant) + inhibitor<br />		**[[2zmd]], [[5ap3]], [[5ap4]], [[5ap5]], [[5ap6]], [[5ap7]], [[5o91]], [[5ntt]], [[5nad]], [[5mrb]] - hTTK kinase domain (mutant) + inhibitor<br />

Alexander Berchansky at 10:50, 10 March 2019

Alexander Berchansky — Sun, 10 Mar 2019 10:50:09 GMT

←Older revision		Revision as of 10:50, 10 March 2019
Line 6:		Line 6:
	== Structural highlights ==		== Structural highlights ==

-	The dual specificity protein kinase '''TTK''' or '''monopolar spindle kinase 1''' contains tetratricopeptide repeat domain (TPR) which serves as interaction domain between proteins. The TPR domain is a helical 34 amino acid motif which is found in several copies in a protein which fold together forming a protein-protein binding domain. Cancer therapy potential drugs bind in <scene name='46/468134/Cv/2'>TTK active site</scene>.<ref>PMID:9779990</ref><ref>PMID:21159646</ref>	+	The dual specificity protein kinase '''TTK''' or '''monopolar spindle kinase 1''' contains tetratricopeptide repeat domain (TPR) which serves as interaction domain between proteins. The TPR domain is a helical 34 amino acid motif which is found in several copies in a protein which fold together forming a protein-protein binding domain. Cancer therapy potential drugs bind in <scene name='46/468134/Cv/3'>TTK active site</scene>.<ref>PMID:9779990</ref><ref>PMID:21159646</ref>
	</StructureSection>		</StructureSection>
	==3D structures of dual specificity protein kinase==		==3D structures of dual specificity protein kinase==

Joel L. Sussman at 19:30, 10 May 2018

Joel L. Sussman — Thu, 10 May 2018 19:30:23 GMT

←Older revision		Revision as of 19:30, 10 May 2018
Line 1:		Line 1:
-	<StructureSection load='~~2x9e~~' size='400' side='right' scene='46/468134/Cv/1' caption='Dual specificity protein kinase TTK kinase domain complex with inhibitor, [[2x9e]]'>	+	<StructureSection load='' size='400' side='right' scene='46/468134/Cv/1' caption='Dual specificity protein kinase TTK kinase domain complex with inhibitor, [[2x9e]]'>
	== Function ==		== Function ==

Michal Harel at 09:27, 9 May 2018

Michal Harel — Wed, 09 May 2018 09:27:16 GMT

←Older revision		Revision as of 09:27, 9 May 2018
Line 13:		Line 13:
	{{#tree:id=OrganizedByTopic\|openlevels=0\|		{{#tree:id=OrganizedByTopic\|openlevels=0\|

-	*CLK1	+	*CLK1 kinase domain

-	**[[1z57]] – hCLK1 ~~kinase domain~~ + himenialdizine – human	+	**[[1z57]] – hCLK1 + himenialdizine – human

-	**[[2vag]] - hCLK1 ~~kinase domain~~ + ~~indole~~ inhibitor<br />	+	**[[5j1v]], [[5j1w]], [[2vag]], [[5x8i]] – hCLK1 + inhibitor<br />
-	**[[~~5j1v]], [[5j1w~~]] – hCLK1 ~~kinase domain~~ + ~~quinazoline~~ inhibitor<br />	+	**[[6g33]] – hCLK1 + iodotubercidine inhibitor<br />

-	*CLK2	+	*CLK2 kinase domain

-	**[[3nr9]] – hCLK2 ~~kinase domain~~	+	**[[3nr9]] – hCLK2<br />
		+	**[[5unp]] – hCLK2 + inhibitor<br />

	*CLK3		*CLK3
Line 36:		Line 37:
	*TTK		*TTK

-	**[[3cek]], [[3dbq]] – hTTK kinase domain<br />	+	**[[3cek]], [[3dbq]], [[2zmc]] – hTTK kinase domain<br />
	**[[4b94]], [[4h7x]], [[4h7y]] - hTTK TPR domain<br />		**[[4b94]], [[4h7x]], [[4h7y]] - hTTK TPR domain<br />
	**[[3gfw]] - hTTK kinase domain + pyrolo-pyridin ligand		**[[3gfw]] - hTTK kinase domain + pyrolo-pyridin ligand
Line 42:		Line 43:
	**[[3h9f]] - hTTK kinase domain + pyrimidino-diazepin ligand		**[[3h9f]] - hTTK kinase domain + pyrimidino-diazepin ligand

-	**[[2x9e]], [[3vqu]], [[3w1f]], [[4bhz]], [[4bi0]], [[4bi1]], [[4bi2]], [[4c4e]], [[4c4f]], [[4c4g]], [[4c4h]], [[4c4i]], [[4c4j]], [[4js8]], [[4jt3]], [[3wzj]], [[3wzk]], [[4o6l]], [[5ehl]], [[5eho]], [[5ehy]], [[5ei2]], [[5ei6]], [[5ei8]], [[5ap0]], [[5ap1]], [[5ap2]], [[5eh0]], [[4zeg]] - hTTK kinase domain + inhibitor	+	**[[2x9e]], [[3vqu]], [[3w1f]], [[4bhz]], [[4bi0]], [[4bi1]], [[4bi2]], [[4c4e]], [[4c4f]], [[4c4g]], [[4c4h]], [[4c4i]], [[4c4j]], [[4js8]], [[4jt3]], [[3wzj]], [[3wzk]], [[4o6l]], [[5ehl]], [[5eho]], [[5ehy]], [[5ei2]], [[5ei6]], [[5ei8]], [[5ap0]], [[5ap1]], [[5ap2]], [[5eh0]], [[4zeg]], [[6b4w]], [[5na0]], [[5n9s]], [[5n93]], [[5n87]], [[5n84]], [[5n7v]] - hTTK kinase domain + inhibitor

-	**[[2zmc]] - hTTK kinase domain	+	**[[2zmd]], [[5ap3]], [[5ap4]], [[5ap5]], [[5ap6]], [[5ap7]], [[5o91]], [[5ntt]], [[5nad]], [[5mrb]] - hTTK kinase domain (mutant) + inhibitor<br />
-		+
-	**[[2zmd]], [[5ap3]], [[5ap4]], [[5ap5]], [[5ap6]], [[5ap7]] - hTTK kinase domain (mutant) + inhibitor<br />	+

	**[[3hmn]] - hTTK kinase domain + ATP		**[[3hmn]] - hTTK kinase domain + ATP

Michal Harel at 10:19, 26 April 2017

Michal Harel — Wed, 26 Apr 2017 10:19:01 GMT

←Older revision		Revision as of 10:19, 26 April 2017
Line 6:		Line 6:
	== Structural highlights ==		== Structural highlights ==

-	The dual specificity protein kinase '''TTK''' contains tetratricopeptide repeat domain (TPR) which serves as interaction domain between proteins. The TPR domain is a helical 34 amino acid motif which is found in several copies in a protein which fold together forming a protein-protein binding domain. Cancer therapy potential drugs bind in <scene name='46/468134/Cv/2'>TTK active site</scene>.<ref>PMID:9779990</ref><ref>PMID:21159646</ref>	+	The dual specificity protein kinase '''TTK''' or '''monopolar spindle kinase 1''' contains tetratricopeptide repeat domain (TPR) which serves as interaction domain between proteins. The TPR domain is a helical 34 amino acid motif which is found in several copies in a protein which fold together forming a protein-protein binding domain. Cancer therapy potential drugs bind in <scene name='46/468134/Cv/2'>TTK active site</scene>.<ref>PMID:9779990</ref><ref>PMID:21159646</ref>
	</StructureSection>		</StructureSection>
	==3D structures of dual specificity protein kinase==		==3D structures of dual specificity protein kinase==

Michal Harel at 09:55, 26 April 2017

Michal Harel — Wed, 26 Apr 2017 09:55:19 GMT

←Older revision		Revision as of 09:55, 26 April 2017
Line 17:		Line 17:
	**[[1z57]] – hCLK1 kinase domain + himenialdizine – human		**[[1z57]] – hCLK1 kinase domain + himenialdizine – human

-	**[[2vag]] - hCLK1 kinase domain + indole inhibitor	+	**[[2vag]] - hCLK1 kinase domain + indole inhibitor<br />
		+	**[[5j1v]], [[5j1w]] – hCLK1 kinase domain + quinazoline inhibitor<br />

	*CLK2		*CLK2
Line 41:		Line 42:
	**[[3h9f]] - hTTK kinase domain + pyrimidino-diazepin ligand		**[[3h9f]] - hTTK kinase domain + pyrimidino-diazepin ligand

-	**[[2x9e]], [[3vqu]], [[3w1f]], [[4bhz]], [[4bi0]], [[4bi1]], [[4bi2]], [[4c4e]], [[4c4f]], [[4c4g]], [[4c4h]], [[4c4i]], [[4c4j]], [[4js8]], [[4jt3]], [[3wzj]], [[3wzk]], [[4o6l]] - hTTK kinase domain + inhibitor	+	**[[2x9e]], [[3vqu]], [[3w1f]], [[4bhz]], [[4bi0]], [[4bi1]], [[4bi2]], [[4c4e]], [[4c4f]], [[4c4g]], [[4c4h]], [[4c4i]], [[4c4j]], [[4js8]], [[4jt3]], [[3wzj]], [[3wzk]], [[4o6l]], [[5ehl]], [[5eho]], [[5ehy]], [[5ei2]], [[5ei6]], [[5ei8]], [[5ap0]], [[5ap1]], [[5ap2]], [[5eh0]], [[4zeg]] - hTTK kinase domain + inhibitor

	**[[2zmc]] - hTTK kinase domain		**[[2zmc]] - hTTK kinase domain

-	**[[2zmd]] - hTTK kinase domain (mutant) + inhibitor	+	**[[2zmd]], [[5ap3]], [[5ap4]], [[5ap5]], [[5ap6]], [[5ap7]] - hTTK kinase domain (mutant) + inhibitor<br />

	**[[3hmn]] - hTTK kinase domain + ATP		**[[3hmn]] - hTTK kinase domain + ATP
Line 51:		Line 52:
	**[[3hmo]] - hTTK kinase domain + staurosporine		**[[3hmo]] - hTTK kinase domain + staurosporine

-	**[[3hmp]] - hTTK kinase domain + ~~quinazolin~~ ligand	+	**[[3hmp]] - hTTK kinase domain + quinazoline ligand<br />
		+	**[[5ljj]] - hTTK kinase domain + reversine<br />
	}}		}}
	== References ==		== References ==
	<references/>		<references/>
	[[Category:Topic Page]]		[[Category:Topic Page]]

Alexander Berchansky at 19:33, 5 January 2016

Alexander Berchansky — Tue, 05 Jan 2016 19:33:39 GMT

←Older revision		Revision as of 19:33, 5 January 2016
Line 6:		Line 6:
	== Structural highlights ==		== Structural highlights ==

-	The dual specificity protein kinase '''TTK''' contains tetratricopeptide repeat domain (TPR) which serves as interaction domain between proteins. The TPR domain is a helical 34 amino acid motif which is found in several copies in a protein which fold together forming a protein-protein binding domain. Cancer therapy potential drugs bind in TTK active site.<ref>PMID:9779990</ref>, <ref>PMID:21159646</ref>	+	The dual specificity protein kinase '''TTK''' contains tetratricopeptide repeat domain (TPR) which serves as interaction domain between proteins. The TPR domain is a helical 34 amino acid motif which is found in several copies in a protein which fold together forming a protein-protein binding domain. Cancer therapy potential drugs bind in <scene name='46/468134/Cv/2'>TTK active site</scene>.<ref>PMID:9779990</ref><ref>PMID:21159646</ref>
	</StructureSection>		</StructureSection>
	==3D structures of dual specificity protein kinase==		==3D structures of dual specificity protein kinase==